A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection (JS001) in Combination With Standard Chemotherapy Versus Placebo in Combination With Standard Chemotherapy as the 1st-line Therapy for Treatment-naive Subjects With PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma
Latest Information Update: 13 Jul 2026
At a glance
- Drugs Toripalimab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Carcinoma; Urogenital cancer
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Junshi Biosciences
Most Recent Events
- 09 Jul 2026 Status changed from not yet recruiting to withdrawn prior to enrolment as study was not conducted.
- 01 Oct 2020 New trial record